SCHEMBL14949246

SCHEMBL14949246

CCOc1cc(Oc2ccc(-c3nnc(Nc4cc(C)c(Cl)c(C)c4)[nH]3)cc2)nc(N)n1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.38
RAB9A P51151 4/20 0.37
ALDH1A1 P00352 3/20 0.37
NPC1 O15118 3/20 0.36
MAPK1 P28482 1/20 0.35
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
MAPT P10636 4/20 0.33
HPGD P15428 2/20 0.33
KDM4E B2RXH2 2/20 0.33
NUDT1 P36639 1/20 0.33
ATM Q13315 1/20 0.32
JAK2 O60674 1/20 0.32
HTT P42858 1/20 0.32
TBK1 Q9UHD2 1/20 0.32
SCN5A Q14524 1/20 0.31
SCN9A Q15858 1/20 0.31
TP53 P04637 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14949248 0.91 SMN1; SMN2 (0.38) SMN1; SMN2RAB9AALDH1A1NPC1MAPK1
SCHEMBL14949254 0.90 RAB9A (0.38) SMN1; SMN2RAB9AALDH1A1NPC1MAPK1
SCHEMBL12336255 0.87 PDGFRB (0.33) SMN1; SMN2RAB9AALDH1A1MAPTKDM4E
SCHEMBL14949247 0.85 RAB9A (0.37) SMN1; SMN2RAB9AALDH1A1NPC1MAPK1
SCHEMBL14949265 0.83 NUDT1 (0.38) SMN1; SMN2RAB9AALDH1A1NPC1MAPK1
SCHEMBL14949504 0.81 KDR (0.38) SMN1; SMN2RAB9AALDH1A1NPC1MAPK1
SCHEMBL12336276 0.80 PDGFRB (0.49) ALDH1A1MAPTKDM4EHTT
SCHEMBL13547690 0.79 PDGFRB (0.36) SMN1; SMN2RAB9AALDH1A1NPC1KMT2A
SCHEMBL12336247 0.79 PDGFRB (0.35) SMN1; SMN2RAB9AALDH1A1MAPK1KMT2A
SCHEMBL14949252 0.77 DHFR (0.35) SMN1; SMN2RAB9AALDH1A1NPC1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION MAP4K2, MAP3K20, MAP3K19 SMN1; SMN2 4181/4885RAB9A 1281/4885ALDH1A1 3693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.